Actively Recruiting
Cerebellum-based Imaging Neural Markers for Antipsychotic Response
Led by Northwell Health · Updated on 2026-04-06
120
Participants Needed
1
Research Sites
239 weeks
Total Duration
On this page
Sponsors
N
Northwell Health
Lead Sponsor
N
National Institute of Mental Health (NIMH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study will investigate neural markers in the cerebellar-cortical circuitry that predict treatment response to antipsychotics in first-episode psychosis. A total of 120 patients diagnosed with a first-episode psychotic disorder will be recruited. All subjects receive naturalistic treatment with either risperidone or aripiprazole for 12 weeks, with dosage and titration followed by standard clinical care. A comprehensive clinical and neuroimaging assessments will be performed before and after treatment.
CONDITIONS
Official Title
Cerebellum-based Imaging Neural Markers for Antipsychotic Response
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of a first-episode psychotic disorder including schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, psychotic disorder Not Otherwise Specified (NOS), bipolar disorder with psychosis, or major depressive disorder with psychosis
- Current positive symptoms rated greater than 3 (moderate) on one or more Brief Psychiatric Rating Scale psychosis items: conceptual disorganization, grandiosity, hallucinatory behavior, or unusual thought content
- Early phase of illness defined by antipsychotic drug use of 8 weeks or less in lifetime
- Age between 16 and 40 years
- Competent to sign informed consent
You will not qualify if you...
- Serious neurological or endocrine disorder or brain trauma
- Any medical condition requiring treatment with a medication with psychotropic effects
- Significant risk of suicidal or homicidal behavior
- Cognitive or language limitations or other factors preventing informed consent
- Contraindications to antipsychotic monotherapy
- Contraindications to MR imaging such as pacemaker
- Pregnancy by self report
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zucker Hillside Hospital
Glen Oaks, New York, United States, 11004
Actively Recruiting
Research Team
H
Hengyi Cao
CONTACT
J
Juan Gallego
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here